Glue P
Diamond Therapeutics, Inc., Toronto, ON M5X 1B8, Canada.
ArticlePsilocybin
A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults.
ArticleKetamine
Ketamine Dose and Duration Effects in Internalizing Disorders.
PreprintPsilocybin
A randomized, double-blind, placebo-controlled single-ascending-dose study to identify a non-hallucinogenic dose of psilocybin in healthy adults
ArticleKetamine
Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study.
ArticleKetamine
Ketamine Dosing Across Clinical Indications: A Narrative Review Organized by Proposed NMDA-Related Mechanisms.
ArticlePsilocybin
Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.
ArticleKetamine
Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study.
ArticlePsychedelics
Systematic Review of the Effect of Psychedelic-Assisted Therapy on Attitudes Toward Death, Life, and Spirituality on Symptoms of Distress, Depression, and/or Anxiety in Patients with Life-Threatening Illness.
ArticleKetamine
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.
ArticleMDMA
Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.
ArticleKetamine
Protocol for a randomised controlled trial of ketamine versus ketamine and behavioural activation therapy for adults with treatment-resistant depression in the community.
ArticleKetamine
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.
ArticleKetamine